The introduction of amyloid-directed monoclonal antibody therapies (mAbs) heralds a new, exciting era for the Alzheimer's disease community. The
Contact:
Phone: 781-464-2000
WEB: www.biogen.com
(C) 2022 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
221.4 USD | +1.80% | +2.75% | -14.43% |
05-03 | HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating | MT |
04-30 | Wall Street: buoyed by Tesla, confident ahead of FOMC meeting | CF |
The introduction of amyloid-directed monoclonal antibody therapies (mAbs) heralds a new, exciting era for the Alzheimer's disease community. The
Contact:
Phone: 781-464-2000
WEB: www.biogen.com
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-14.43% | 31.67B | |
-3.89% | 88.14B | |
+1.45% | 40.51B | |
+51.20% | 24.62B | |
-14.85% | 15.65B | |
-13.87% | 12.07B | |
-7.87% | 11.97B | |
-39.40% | 11.61B | |
+5.62% | 8.81B | |
-5.26% | 8.5B |